These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25128043)

  • 1. PRO data collection in clinical trials using mixed modes: report of the ISPOR PRO mixed modes good research practices task force.
    Eremenco S; Coons SJ; Paty J; Coyne K; Bennett AV; McEntegart D;
    Value Health; 2014 Jul; 17(5):501-16. PubMed ID: 25128043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force.
    Matza LS; Patrick DL; Riley AW; Alexander JJ; Rajmil L; Pleil AM; Bullinger M
    Value Health; 2013 Jun; 16(4):461-79. PubMed ID: 23796280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of electronic systems to collect patient-reported outcome (PRO) data-recommendations for clinical trial teams: report of the ISPOR ePRO systems validation good research practices task force.
    Zbrozek A; Hebert J; Gogates G; Thorell R; Dell C; Molsen E; Craig G; Grice K; Kern S; Hines S
    Value Health; 2013 Jun; 16(4):480-9. PubMed ID: 23796281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of the Task Force Report on PRO data collection in clinical trials using mixed modes.
    McLeod L
    Value Health; 2014 Jul; 17(5):491-2. PubMed ID: 25128040
    [No Abstract]   [Full Text] [Related]  

  • 6. Updated Recommendations on Evidence Needed to Support Measurement Comparability Among Modes of Data Collection for Patient-Reported Outcome Measures: A Good Practices Report of an ISPOR Task Force.
    O'Donohoe P; Reasner DS; Kovacs SM; Byrom B; Eremenco S; Barsdorf AI; Arnera V; Coons SJ
    Value Health; 2023 May; 26(5):623-633. PubMed ID: 37121630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The patient-reported outcome (PRO) consortium: filling measurement gaps for PRO end points to support labeling claims.
    Coons SJ; Kothari S; Monz BU; Burke LB
    Clin Pharmacol Ther; 2011 Nov; 90(5):743-8. PubMed ID: 21993428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multinational trials-recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force report.
    Wild D; Eremenco S; Mear I; Martin M; Houchin C; Gawlicki M; Hareendran A; Wiklund I; Chong LY; von Maltzahn R; Cohen L; Molsen E
    Value Health; 2009 Jun; 12(4):430-40. PubMed ID: 19138309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.
    Acquadro C; Berzon R; Dubois D; Leidy NK; Marquis P; Revicki D; Rothman M;
    Value Health; 2003; 6(5):522-31. PubMed ID: 14627058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report.
    Rothman M; Burke L; Erickson P; Leidy NK; Patrick DL; Petrie CD
    Value Health; 2009; 12(8):1075-83. PubMed ID: 19804437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using factor analysis to confirm the validity of children's self-reported health-related quality of life across different modes of administration.
    Varni JW; Limbers CA; Newman DA
    Clin Trials; 2009 Apr; 6(2):185-95. PubMed ID: 19342471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
    Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
    Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report.
    Benjamin K; Vernon MK; Patrick DL; Perfetto E; Nestler-Parr S; Burke L
    Value Health; 2017; 20(7):838-855. PubMed ID: 28712612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life.
    Wiklund I
    Fundam Clin Pharmacol; 2004 Jun; 18(3):351-63. PubMed ID: 15147288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equivalence of electronic and paper-and-pencil administration of patient-reported outcome measures: a meta-analytic review.
    Gwaltney CJ; Shields AL; Shiffman S
    Value Health; 2008; 11(2):322-33. PubMed ID: 18380645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical applications of usability theory to electronic data collection for clinical trials.
    Schmier JK; Kane DW; Halpern MT
    Contemp Clin Trials; 2005 Jun; 26(3):376-85. PubMed ID: 15911471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.